(ATOS) Atossa Genetics - Overview
Stock: Oral Endoxifen, Car-T Pipeline
| Risk 5d forecast | |
|---|---|
| Volatility | 60.9% |
| Relative Tail Risk | -8.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.77 |
| Alpha | -75.45 |
| Character TTM | |
|---|---|
| Beta | 1.148 |
| Beta Downside | 1.077 |
| Drawdowns 3y | |
|---|---|
| Max DD | 83.21% |
| CAGR/Max DD | -0.26 |
Description: ATOS Atossa Genetics January 20, 2026
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a Seattle-based clinical-stage biopharma focused on unmet oncology needs, principally breast cancer. Its lead asset, oral (Z)-endoxifen-a potent tamoxifen metabolite-currently resides in a Phase II trial evaluating both treatment and preventive indications. The company also maintains early-stage programs in immunotherapy and chimeric antigen receptor (CAR) therapy, and it rebranded from Atossa Genetics to Atossa Therapeutics in January 2020.
Key quantitative signals (as of the most recent 10-Q filing) include a market capitalization of roughly $150 million, cash and equivalents of about $30 million, and a net loss of $25 million for the trailing twelve months, giving an estimated 12-month cash runway of ~14 months assuming current burn rates. The global breast-cancer therapeutics market is projected to exceed $30 billion by 2028 (CAGR ≈ 6 %), providing a sizable addressable market for a low-cost oral agent. However, the Phase II trial’s primary endpoint timing and regulatory pathway remain uncertain, and any delay could materially affect liquidity.
For a deeper quantitative view of ATOS’s risk-adjusted upside, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -20.70 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.45 > 3% & CFO -26.3m > Net Income -30.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.2m) vs 12m ago 2.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: -15.26 > 6 (EBITDA TTM -32.3m / Interest Expense TTM -2.12m) |
Altman Z'' -15.00
| A: 0.82 (Total Current Assets 55.7m - Total Current Liabilities 8.22m) / Total Assets 58.0m |
| B: -4.06 (Retained Earnings -235.6m / Total Assets 58.0m) |
| C: -0.47 (EBIT TTM -32.3m / Avg Total Assets 68.7m) |
| D: -25.79 (Book Value of Equity -212.1m / Total Liabilities 8.22m) |
| Altman-Z'' Score: -38.11 = D |
What is the price of ATOS shares?
Over the past week, the price has changed by -36.99%, over one month by -46.09%, over three months by -56.29% and over the past year by -55.78%.
Is ATOS a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.8 | 7.7% |
| Analysts Target Price | 5.8 | 7.7% |
| ValueRay Target Price | 4.8 | -10.3% |
ATOS Fundamental Data Overview February 02, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -32.3m USD
EBITDA TTM = -32.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -51.8m USD (from netDebt column, last quarter)
Enterprise Value = -47.0m USD (4.87m + (null Debt) - CCE 51.8m)
Interest Coverage Ratio = -15.26 (Ebit TTM -32.3m / Interest Expense TTM -2.12m)
EV/FCF = 1.79x (Enterprise Value -47.0m / FCF TTM -26.3m)
FCF Yield = 55.96% (FCF TTM -26.3m / Enterprise Value -47.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 16.0k) / Revenue TTM)
Tobins Q-Ratio = -0.81 (set to none) (Enterprise Value -47.0m / Total Assets 58.0m)
Interest Expense / Debt = unknown (Interest Expense 820.0k / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -25.5m (EBIT -32.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.77 (Total Current Assets 55.7m / Total Current Liabilities 8.22m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 1.61 (negative EBITDA) (Net Debt -51.8m / EBITDA -32.3m)
Debt / FCF = 1.97 (negative FCF - burning cash) (Net Debt -51.8m / FCF TTM -26.3m)
Total Stockholder Equity = 61.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.90% (Net Income -30.2m / Total Assets 58.0m)
RoE = -49.42% (Net Income TTM -30.2m / Total Stockholder Equity 61.1m)
RoCE = -64.87% (EBIT -32.3m / Capital Employed (Total Assets 58.0m - Current Liab 8.22m))
RoIC = -41.78% (negative operating profit) (NOPAT -25.5m / Invested Capital 61.1m)
WACC = 10.14% (E(4.87m)/V(4.87m) * Re(10.14%) + (debt-free company))
Discount Rate = 10.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.53%
Fair Price DCF = unknown (Cash Flow -26.3m)
EPS Correlation: -34.43 | EPS CAGR: -18.96% | SUE: -0.56 | # QB: 0
Revenue Correlation: 8.61 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.07 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.29 | Chg30d=-0.003 | Revisions Net=-2 | Growth EPS=-14.7% | Growth Revenue=+0.0%